{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:59:57Z","timestamp":1783792797104,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rift Valley fever virus (RVFV) is an emerging mosquito-borne bunyavirus that is highly pathogenic to wild and domesticated ruminants, camelids, and humans. While animals are exclusively infected via mosquito bites, humans can also be infected via contact with contaminated tissues or blood. No human vaccine is available and commercialized veterinary vaccines do not optimally combine efficacy with safety. We previously reported the development of two novel live-attenuated RVF vaccines, created by splitting the M genome segment and deleting the major virulence determinant NSs. The vaccine candidates, referred to as the veterinary vaccine vRVFV-4s and the human vaccine hRVFV-4s, were shown to induce protective immunity in multiple species after a single vaccination. Anticipating accidental exposure of humans to the veterinary vaccine and the application of hRVFV-4s to humans, the safety of each vaccine was evaluated in the most susceptible nonhuman primate model, the common marmoset (\n                    <jats:italic>Callithrix jacchus<\/jats:italic>\n                    ). Marmosets were inoculated with high doses of each vaccine and were monitored for clinical signs as well as for vaccine virus dissemination, shedding, and spreading to the environment. To accurately assess the attenuation of both vaccine viruses, separate groups of marmosets were inoculated with the parent wild-type RVFV strains. Both wild-type strains induced high viremia and disseminated to primary target organs, associated with mild-to-severe morbidity. In contrast, both vaccines were well tolerated with no evidence of dissemination and shedding while inducing potent neutralizing antibody responses. The results of the studies support the unprecedented safety profile of both vaccines for animals and humans.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00476-y","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T06:02:54Z","timestamp":1652853774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Safety and immunogenicity of four-segmented Rift Valley fever virus in the common marmoset"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-2438","authenticated-orcid":false,"given":"Paul J.","family":"Wichgers Schreur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8608-8629","authenticated-orcid":false,"given":"Petra","family":"Mooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4666-0798","authenticated-orcid":false,"given":"Babs E.","family":"Verstrepen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Fagrouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"van Driel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jet","family":"Kant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"van de Water","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4563-8513","authenticated-orcid":false,"given":"Willy M.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucien","family":"van Keulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0912-2074","authenticated-orcid":false,"given":"Ernst J.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kortekaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"476_CR1","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1089\/vbz.2008.0009","volume":"8","author":"S Moutailler","year":"2008","unstructured":"Moutailler, S., Krida, G., Schaffner, F., Vazeille, M. & Failloux, A. B. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis. 8, 749\u2013753 (2008).","journal-title":"Vector Borne Zoonotic Dis."},{"key":"476_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1093\/jmedent\/45.1.102","volume":"45","author":"MJ Turell","year":"2008","unstructured":"Turell, M. J. et al. Vector competence of selected African mosquito (Diptera: Culicidae) species for Rift Valley fever virus. J. Med. Entomol. 45, 102\u2013108 (2008).","journal-title":"J. Med. Entomol."},{"key":"476_CR3","doi-asserted-by":"publisher","unstructured":"Bron, G. M. et al. Over 100 years of Rift Valley fever: a patchwork of data on pathogen spread and spillover. Pathogens 10. https:\/\/doi.org\/10.3390\/pathogens10060708 (2021).","DOI":"10.3390\/pathogens10060708"},{"key":"476_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"476_CR5","doi-asserted-by":"publisher","first-page":"e864","DOI":"10.1016\/S2214-109X(16)30176-0","volume":"4","author":"M Baudin","year":"2016","unstructured":"Baudin, M. et al. Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a cross-sectional study. Lancet Glob. Health 4, e864\u2013e871 (2016).","journal-title":"Lancet Glob. Health"},{"key":"476_CR6","doi-asserted-by":"publisher","first-page":"eaau9812","DOI":"10.1126\/sciadv.aau9812","volume":"4","author":"CM McMillen","year":"2018","unstructured":"McMillen, C. M. et al. Rift Valley fever virus induces fetal demise in Sprague-Dawley rats through direct placental infection. Sci. Adv. 4, eaau9812 (2018).","journal-title":"Sci. Adv."},{"key":"476_CR7","doi-asserted-by":"publisher","first-page":"e0007898","DOI":"10.1371\/journal.pntd.0007898","volume":"14","author":"J Oymans","year":"2020","unstructured":"Oymans, J., Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas. PLoS Negl. Trop. Dis. 14, e0007898 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"476_CR8","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12985-016-0573-8","volume":"13","author":"HJ Ly","year":"2016","unstructured":"Ly, H. J. & Ikegami, T. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Virol. J. 13, 118 (2016).","journal-title":"Virol. J."},{"key":"476_CR9","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1128\/JVI.01238-07","volume":"81","author":"S Won","year":"2007","unstructured":"Won, S., Ikegami, T., Peters, C. J. & Makino, S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J. Virol. 81, 13335\u201313345 (2007).","journal-title":"J. Virol."},{"key":"476_CR10","doi-asserted-by":"publisher","first-page":"e2670","DOI":"10.1371\/journal.pntd.0002670","volume":"8","author":"RC Kading","year":"2014","unstructured":"Kading, R. C. et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl. Trop. Dis. 8, e2670 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"476_CR11","doi-asserted-by":"publisher","first-page":"e87385","DOI":"10.1371\/journal.pone.0087385","volume":"9","author":"HM Weingartl","year":"2014","unstructured":"Weingartl, H. M. et al. Rift Valley fever virus incorporates the 78 kDa glycoprotein into virions matured in mosquito C6\/36 cells. PloS One 9, e87385 (2014).","journal-title":"PloS One"},{"key":"476_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.71","volume":"3","author":"F Kreher","year":"2014","unstructured":"Kreher, F. et al. The Rift Valley fever accessory proteins NSm and P78\/NSm-GN are distinct determinants of virus propagation in vertebrate and invertebrate hosts. Emerg. Microbes Infect. 3, e71 (2014).","journal-title":"Emerg. Microbes Infect."},{"key":"476_CR13","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1128\/JVI.00961-14","volume":"88","author":"PJ Wichgers Schreur","year":"2014","unstructured":"Wichgers Schreur, P. J., Oreshkova, N., Moormann, R. J. & Kortekaas, J. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging. J. Virol. 88, 10883\u201310893 (2014).","journal-title":"J. Virol."},{"key":"476_CR14","first-page":"155","volume":"50","author":"BJ Barnard","year":"1979","unstructured":"Barnard, B. J. Rift Valley fever vaccine-antibody and immune response in cattle to a live and an inactivated vaccine. J. S Afr. Vet. Assoc. 50, 155\u2013157 (1979).","journal-title":"J. S Afr. Vet. Assoc."},{"key":"476_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","volume":"53","author":"R Muller","year":"1995","unstructured":"Muller, R. et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am. J. Trop. Med Hyg. 53, 405\u2013411 (1995).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"476_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","volume":"75","author":"M Bouloy","year":"2001","unstructured":"Bouloy, M. et al. Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs. J. Virol. 75, 1371\u20131377 (2001).","journal-title":"J. Virol."},{"key":"476_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00212-4","volume":"5","author":"PJ Wichgers Schreur","year":"2020","unstructured":"Wichgers Schreur, P. J. et al. Safety and efficacy of four-segmented Rift Valley fever virus in young sheep, goats and cattle. NPJ Vaccines 5, 65 (2020).","journal-title":"NPJ Vaccines"},{"key":"476_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41577-018-0005-7","volume":"18","author":"JD Estes","year":"2018","unstructured":"Estes, J. D., Wong, S. W. & Brenchley, J. M. Nonhuman primate models of human viral infections. Nat. Rev. Immunol. 18, 390\u2013404 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"476_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF01311288","volume":"110","author":"JC Morrill","year":"1990","unstructured":"Morrill, J. C. et al. Pathogenesis of Rift Valley fever in rhesus monkeys: role of interferon response. Arch. Virol. 110, 195\u2013212 (1990).","journal-title":"Arch. Virol."},{"key":"476_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/BF01311021","volume":"99","author":"CJ Peters","year":"1988","unstructured":"Peters, C. J. et al. Experimental Rift Valley fever in rhesus macaques. Arch. Virol. 99, 31\u201344 (1988).","journal-title":"Arch. Virol."},{"key":"476_CR21","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/JVI.06190-11","volume":"86","author":"DR Smith","year":"2012","unstructured":"Smith, D. R. et al. Development of a novel nonhuman primate model for Rift Valley fever. J. Virol. 86, 2109\u20132120 (2012).","journal-title":"J. Virol."},{"key":"476_CR22","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1128\/JVI.02341-13","volume":"88","author":"AL Hartman","year":"2014","unstructured":"Hartman, A. L. et al. Aerosolized Rift Valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. J. Virol. 88, 2235\u20132245 (2014).","journal-title":"J. Virol."},{"key":"476_CR23","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fmicb.2016.00287","volume":"7","author":"PJ Wichgers Schreur","year":"2016","unstructured":"Wichgers Schreur, P. J. et al. Co-housing of Rift Valley fever virus infected lambs with immunocompetent or immunosuppressed lambs does not result in virus transmission. Front Microbiol 7, 287 (2016).","journal-title":"Front Microbiol"},{"key":"476_CR24","doi-asserted-by":"publisher","first-page":"e0189250","DOI":"10.1371\/journal.pone.0189250","volume":"12","author":"T Ikegami","year":"2017","unstructured":"Ikegami, T. et al. Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model. PLoS One 12, e0189250 (2017).","journal-title":"PLoS One"},{"key":"476_CR25","doi-asserted-by":"publisher","first-page":"e0006474","DOI":"10.1371\/journal.pntd.0006474","volume":"12","author":"DR Smith","year":"2018","unstructured":"Smith, D. R. et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Neglected Tropical Dis. 12, e0006474 (2018).","journal-title":"PLoS Neglected Tropical Dis."},{"key":"476_CR26","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1128\/JVI.00841-11","volume":"85","author":"J Kortekaas","year":"2011","unstructured":"Kortekaas, J. et al. Creation of a nonspreading Rift Valley fever virus. J. Virol. 85, 12622\u201312630 (2011).","journal-title":"J. Virol."},{"key":"476_CR27","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.vaccine.2017.04.024","volume":"35","author":"PJ Wichgers Schreur","year":"2017","unstructured":"Wichgers Schreur, P. J., van Keulen, L., Kant, J. & Kortekaas, J. Four-segmented Rift Valley fever virus-based vaccines can be applied safely in ewes during pregnancy. Vaccine 35, 3123\u20133128 (2017).","journal-title":"Vaccine"},{"key":"476_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jviromet.2017.06.001","volume":"248","author":"PJ Wichgers Schreur","year":"2017","unstructured":"Wichgers Schreur, P. J., Paweska, J. T., Kant, J. & Kortekaas, J. A novel highly sensitive, rapid and safe Rift Valley fever virus neutralization test. J. Virological Methods 248, 26\u201330 (2017).","journal-title":"J. Virological Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00476-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00476-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T09:39:00Z","timestamp":1669282740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00476-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["476"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00476-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1075403\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.J.W.S. and J.Ko. are inventors of WIPO Patent Application WO\/2014\/189372 \u201cBunyaviruses with segmented glycoprotein genes and methods for generating these viruses\u201d, owned by BunyaVax B.V. C.P. is the Chief Executive Officer and P.J.W.S. is non-executive Scientific Officer of BunyaVax. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}